Several studies revealed that some cancer-associated AS variants, such as CD44 and VEGF (vascular endothelial growth factor) receptor, played an important role in cancer-targeted therapies (Heider et al., 2004; Sampson et al., 2008). This evidence concerns the gene VEGFA and cancer.